Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 20/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342294 | 0.92 | GABRG2 (0.46) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL341628 | 0.92 | GABRG2 (0.46) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL6768900 | 0.91 | GABRG2 (0.46) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL6774691 | 0.85 | GABRG2 (0.56) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL7865946 | 0.83 | GABRG2 (0.43) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL7865947 | 0.83 | GABRG2 (0.43) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL341950 | 0.83 | GABRG2 (0.44) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL6779109 | 0.82 | GABRG2 (0.43) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL342117 | 0.81 | GABRG2 (0.56) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL341479 | 0.81 | GABRG2 (0.65) | GABRG2GABRB3GABRA3GABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063714-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | CARLING WILLIAM ROBERT (GB) | 2004-04-01 | — | — | US | claimed |
| US-6828322-B2 | Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine | MERCK SHARP & DOHME LTD. | 2004-12-07 | — | — | US | disclosed |
| US-20040063714-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | CARLING WILLIAM ROBERT (GB) | 2004-04-01 | — | — | US | disclosed |
| US-6579875-B1 | Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine | MERCK SHARP & DOHME LIMITED | 2003-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063714-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | GABRA3, GABBR1, GABRA2 | GABRG2 15/4885GABRB3 6/4885GABRA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.